Zentalis Pharmaceuticals Inc expected to post a loss of 91 cents a share - Earnings Preview

Zentalis Pharmaceuticals

06/11/2024 14:08

* Zentalis Pharmaceuticals Inc  ZNTL.OQ   ZNTL.O  is
expected
to show no change in quarterly revenue when it reports 
results on November 8 (estimated) for the period ending
September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Zentalis Pharmaceuticals
Inc
is for a loss of 91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $8.00​, above​ its last closing price
of $3.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.87       -0.84      -1.24     Missed  -47.5
 Mar. 31 0001  -0.76       -0.77      0.14      Beat    118.3
 Dec. 31 2023  -0.94       -0.92      -0.93     Missed  -1.5​
 Jan. 1 0001   -0.91       -0.91      -0.79     Beat    13.3
 ​​Jun.        -1.02       -1.04      -1.85     Missed  -78.3
 30 2023                                                
 Mar. 31 2023  -0.98       -1.02      -0.92     Beat    -5​
 Jan. 1 0001   -1.01       -1.06      -0.92     Beat    13.2
 Jan. 1 0001   -1.15       -1.17      -0.96     Beat    17.9
 This summary was machine generated November 6 at 14:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)